IXICO plc Collaboration with leading pharmaceutical co in MS (7419B)
09 October 2015 - 5:00PM
UK Regulatory
TIDMIXI
RNS Number : 7419B
IXICO plc
09 October 2015
IXICO announces strategic collaboration with leading
pharmaceutical company to develop and pilot an adapted version of
Assessa(R) for the clinical management of multiple sclerosis
9 October 2015, IXICO plc (Ticker: IXI) ('IXICO' or the
'Company'), the brain health company, today announces that it has
entered into a strategic collaboration with a leading
pharmaceutical company and independent expert clinical centres in
the management of multiple sclerosis.
Under the terms of the multi-stage collaboration, IXICO will
develop an adapted version of Assessa(R), its CE marked digital
healthcare platform, to assist in the monitoring and management of
people receiving approved pharmaceutical treatments for multiple
sclerosis ('MS') in the EU and Canada. The project will start in
October 2015 and it is anticipated that the digital platform will
be deployed in a clinical setting in 2016.
PML
People with MS treated with disease-modifying agents might
develop an increased risk of progressive multifocal
leukoencephalopathy (PML), an opportunistic viral infection of the
brain that usually leads to death or severe disability. PML has a
typical mortality rate of 20-50 percent in the first few months
following diagnosis but this does depend on speed of diagnosis, the
severity of the underlying disease and treatment received. Those
who survive PML can be left with severe neurological
disabilities.
Assessa(R)
Assessa(R) has been developed using IXICO's digital healthcare
technology and combines imaging, demographic, cognitive and
functional information to improve the precision of patient
stratification, differential diagnosis and predict likely disease
progression. To date, it has principally been applied to people
living with dementia. Available in both research and medical device
forms, Assessa(R) can support both stratification of patients in
clinical trials and diagnosis of disease in the clinic.
Strategic collaboration
Under the terms of this new strategic collaboration, IXICO will
develop, validate and pilot an adapted version of Assessa(R) with
leading clinical experts in Europe, specifically to facilitate
remote MRI assessment in the monitoring of patients at increased
risk of PML.
Assessa(R) will provide a digital clinical decision support
platform to more reliably and effectively offer access to second
opinion reading expertise of MRI scans. It will facilitate the
remote transfer and storage of MRI scans, clinical data and
subsequent diagnosis between the treating physician and the second
opinion expert MRI readers. IXICO will be funded to develop,
validate and pilot the adapted version of the Assessa(R) platform
in the context of PML suspicion with the intention to roll out and
operate the platform internationally thereafter.
Professor Derek Hill, Chief Executive of IXICO commented:
'This is an important strategic opportunity for IXICO in that it
represents the first deployment of an adapted version of our
Assessa(R) digital platform to support the safety monitoring of
approved pharmaceutical treatments in the important area of
multiple sclerosis. We expect this collaboration to make a material
contribution to our revenues in the next 12-18 months thereby
underpinning the board's confidence in meeting current market
expectations.'
John Hall, SVP Commercial Operations added:
'We are delighted that this new collaboration will expand the
use of our Assessa(R) platform into another clinical area alongside
currently approved treatments, further extending the reach and
application of our technology and expertise.'
Notes to Editors
About IXICO
IXICO, the brain health company, uses its innovative and
proprietary digital health technologies to help those involved in
researching and treating serious diseases to make rapid, informed
decisions targeted at improving patient outcomes. IXICO has
significant experience in working with global pharmaceutical and
biotechnology companies supporting clinical studies in the field of
neuro-degenerative disorders including Alzheimer's disease,
Huntington's disease, other causes of dementia and Multiple
Sclerosis.
About Assessa(R)
IXICO's digital healthcare technology which can combine imaging,
demographic, cognitive and functional information to improve the
precision of patient stratification, differential diagnosis and
predict likely disease progression of dementia and other
neurodegenerative diseases. Available in both research and medical
device forms, Assessa(R) can support both stratification of
patients in clinical trials and diagnosis of disease in the clinic.
In January 2015, IXICO announced its selection as a partner within
European Prevention of Alzheimer's dementia Initiative (EPAD), to
provide Assessa(R) to more reliably identify subjects with
asymptomatic or early stage Alzheimer's who are most likely to
benefit from treatment. In May 2015 IXICO announced the award of an
Innovate UK grant to support further development of Assessa(R) to
quantify vascular disease burden in patients with CNS diseases. In
June 2015 and recently in August 2015, IXICO announced its
selection by a top 15 pharmaceutical company to provide Assessa(R)
to analyse brain MRI images collected from patient's enrolled in
clinical trials.
More information is available on www.ixico.com
Enquiries:
IXICO plc +44 20 3763 7499
Derek Hill, CEO
Susan Lowther, CFO
Charles Spicer, VP Corporate Development
Peel Hunt LLP (Nominated Adviser
and Broker) +44 20 7418 8900
James Steel
Oliver Jackson
Daniel Stewart & Company (Joint
Broker) +44 207 776 6550
Martin Lampshire
David Coffman
FTI Consulting Limited (Investor
Relations) +44 20 3727 1000
Simon Conway
Matthew Moss
Mo Noonan
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGREANEPELDSFFF
(END) Dow Jones Newswires
October 09, 2015 02:00 ET (06:00 GMT)
Phytopharm (LSE:PYM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Phytopharm (LSE:PYM)
Historical Stock Chart
From Dec 2023 to Dec 2024
